Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors
David E. I. Pyott
IRVINE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced the appointment of David E. I. Pyott, a distinguished leader in the global biopharmaceutical industry and former Chairman and CEO of Allergan, Inc., to its Board of Directors.
“David is one of the most accomplished leaders in eye care, with a strong track record of translating innovation into global impact,” said Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus. “His experience building some of the most successful franchises in our industry will be invaluable as we scale XDEMVY, advance our pipeline and position Tarsus for sustained growth. We are honored to welcome him to our Board.”
Mr. Pyott brings decades of global leadership experience spanning innovative R&D, product development, and commercial execution. During his 17-year tenure as CEO of Allergan, he transformed the company from a focused eye care business with approximately $1 billion in sales into a global specialty pharmaceutical and medical device leader generating more than $7 billion in revenue. He led the company through periods of significant market complexity while maintaining a long-term growth focus and delivering strong commercial performance. In recognition of his leadership, he was named one of Harvard Business Review’s “100 Best Performing CEOs in the World.” Prior to Allergan, Mr. Pyott served as Head of the Novartis Nutrition Division and as a member of the Executive Committee of Novartis AG.
“Tarsus is entering a highly compelling next phase of its evolution, and I’m pleased to join the Board at this important moment in time,” said Mr. Pyott. “Tarsus has already established a remarkable foundation with its lead commercial product and promising pipeline, and I look forward to working with its outstanding Board and management team to help build long-term value and advance further meaningful innovation in eye care and beyond.”
In addition to Tarsus, Mr. Pyott currently serves as a member of the Board of Directors of Alnylam Pharmaceuticals and Pliant Therapeutics. He was previously a member of the Supervisory Board of Royal Philips in the Netherlands, a public diversified health technology company, and a member of the Board of Directors of BioMarin Pharmaceutical Inc.
Mr. Pyott is also Chairman of the Governing Board of the London Business School, Vice President and co-founder of the Ophthalmology Foundation, and a Trustee of the California Institute of Technology.
Mr. Pyott holds a Diploma in International and European Law from the Europa Institute at the University of Amsterdam, an Honorary Degree in Medicine and a Master of Arts degree from the University of Edinburgh, and a Master of Business Administration degree from the London Business School.
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. XDEMVY (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of ocular rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease, all of which are in Phase 2.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Goldman Sachs Global Stock Market Outlook: AI Capital Expenditure to Peak Next Year, Earnings Growth to "Slow Down Significantly", Cloud Giants Become "Defensive Assets"
Goldman Sachs’ 2027 Global Equity Strategy points out that the AI capital expenditure boom is nearing its peak, and global profit growth will slow significantly. S&P 500 earnings growth is expected to drop from 36% to 11%, with depreciation pressures gradually emerging. However, cloud giants’ valuations have adjusted to a forward P/E of 19.7, lower than the staples sector, and are classified as “relatively defensive” assets. Goldman Sachs predicts an S&P 500 target of 8,700 points and suggests overweighting the US and Japan, while underweighting Europe.
With $135 billion worth of Nvidia stock, will Jensen Huang cash out?
After Jensen Huang stepped down, his Nvidia holdings of approximately 812 million shares, valued at $135 billion, became a major pressure on the stock price. Any reduction in holdings is subject to both legal and market constraints: shares can only be sold compliantly after the disclosure of any undisclosed negative information, and the volume is equivalent to six trading days’ total market transactions, meaning large-scale cashouts would have to be spread over several months.
Will the traditional Christmas rally still happen in the US stock market this year?
After a simultaneous technical and position-based recovery in the US stock market, Goldman Sachs, Morgan Stanley, and JPMorgan have successively signaled a year-end rebound. Extremely light positions, mean reversion of valuations, and seasonal support together create conditions for a short squeeze. However, global manufacturing import price inflation has annualized at around 24%, surpassing the pandemic peak, and the inflation bill will come due intensively in the first quarter of next year. Goldman Sachs warns that once the year-end rally materializes, it may exhaust future upside potential.
Anthropic IPO Roadshow: CEO Says "Doesn't Care About Market Conditions", Hopes to "Underpromise and Overdeliver"
As Anthropic gears up for its IPO, CEO Amodei remains deliberately low-key during the roadshow, emphasizing "under-promise and over-deliver," and appears calm regarding market volatility at the time of listing. In response to fluctuations in the AI sector and the Nvidia situation, Amodei stated he is not particularly concerned about the specific month of listing or market conditions, and frankly admits that allocation of computing power is "the most fundamental business challenge."
Crypto prices
More
